X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (217) 217
Publication (30) 30
Newspaper Article (18) 18
Book Chapter (5) 5
Book / eBook (1) 1
Book Review (1) 1
Dissertation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (77) 77
humans (62) 62
hematology (48) 48
female (45) 45
male (45) 45
oncology (45) 45
lymphomas (41) 41
middle aged (40) 40
adult (39) 39
aged (32) 32
antineoplastic combined chemotherapy protocols - therapeutic use (28) 28
chemotherapy (28) 28
rituximab (27) 27
cancer (26) 26
lymphoma (25) 25
young adult (25) 25
treatment outcome (24) 24
article (21) 21
aged, 80 and over (20) 20
care and treatment (18) 18
survival (18) 18
b-cell lymphoma (17) 17
hematology, oncology and palliative medicine (16) 16
lymphoma, large b-cell, diffuse - mortality (16) 16
radiotherapy (16) 16
prognosis (15) 15
non-hodgkins-lymphoma (14) 14
retrospective studies (13) 13
disease-free survival (12) 12
lymphoma, large b-cell, diffuse - drug therapy (12) 12
transplantation (12) 12
adolescent (11) 11
analysis (11) 11
elderly-patients (11) 11
hemic and lymphatic diseases (11) 11
follow-up studies (10) 10
leukemia (10) 10
neoplasm staging (10) 10
therapy (10) 10
patients (9) 9
survival rate (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
diffuse large b-cell lymphoma (8) 8
patient outcomes (8) 8
professional golf (8) 8
survival analysis (8) 8
antibodies, monoclonal, murine-derived - administration & dosage (7) 7
biopsy (7) 7
chop (7) 7
chronic lymphocytic-leukemia (7) 7
disease (7) 7
immune system diseases (7) 7
mantle cell lymphoma (7) 7
multicenter (7) 7
toxicity (7) 7
abridged index medicus (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
cyclophosphamide (6) 6
cyclophosphamide - administration & dosage (6) 6
doxorubicin - administration & dosage (6) 6
doxorubicin - therapeutic use (6) 6
expression (6) 6
gene expression (6) 6
health aspects (6) 6
lymphocytes b (6) 6
lymphoma, large b-cell, diffuse - diagnosis (6) 6
lymphoma, large b-cell, diffuse - pathology (6) 6
medical prognosis (6) 6
medical research (6) 6
methotrexate (6) 6
non-hodgkin lymphoma (6) 6
non-hodgkin-lymphoma (6) 6
phase-ii (6) 6
recurrence (6) 6
rituximab - administration & dosage (6) 6
salvage therapy - methods (6) 6
surgery (6) 6
anthracyclines (5) 5
antimitotic agents (5) 5
antineoplastic agents (5) 5
biomarkers (5) 5
cell biology (5) 5
chemotherapy plus rituximab (5) 5
clinical trials (5) 5
cyclophosphamide - adverse effects (5) 5
cyclophosphamide - therapeutic use (5) 5
development and progression (5) 5
dexamethasone - administration & dosage (5) 5
diagnosis (5) 5
diffuse large b‐cell lymphoma (5) 5
follicular lymphoma (5) 5
immunotherapy (5) 5
lymphocytes t (5) 5
lymphoma - drug therapy (5) 5
lymphoma, large b-cell, diffuse - genetics (5) 5
multivariate analysis (5) 5
neutropenia (5) 5
radiation (5) 5
radiology (5) 5
radiology, nuclear medicine & medical imaging (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BLOOD, ISSN 0006-4971, 09/2019, Volume 134, Issue 13, pp. 996 - 998
In this issue of Blood, Goy et al report on the promising activity of a phase 1b trial of the targeted therapy triplet rituximab, ibrutinib, and lenalidomide... 
HEMATOLOGY | LYMPHOMA | CELL
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 1, pp. 69 - 77
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 1019 - 1026
Summary Background Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab, cyclophosphamide,... 
Hematology, Oncology and Palliative Medicine | THERAPY | OLDER PATIENTS | ONCOLOGY | FEBRILE NEUTROPENIA | PCI-32765 | CHRONIC LYMPHOCYTIC-LEUKEMIA | CLASSIFICATION | RANDOMIZED CONTROLLED-TRIAL | TARGETING BTK | ELDERLY-PATIENTS | CHEMOTHERAPY | Doxorubicin - therapeutic use | Pyrazoles - therapeutic use | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Dose-Response Relationship, Drug | Young Adult | Non-Randomized Controlled Trials as Topic | Aged, 80 and over | Adult | Female | Lymphoma, Non-Hodgkin - drug therapy | Pyrazoles - adverse effects | Severity of Illness Index | Antigens, CD20 - immunology | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Administration, Oral | Rituximab | Survival Rate | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Antigens, CD20 - drug effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Lymphoma, Non-Hodgkin - diagnosis | Care and treatment | Anthracyclines | Cyclophosphamide | Prednisone | Corticosteroids | Tumors
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 12, pp. 1311 - 1318
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 48 - 56
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2017, Volume 377, Issue 26, pp. 2531 - 2544
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2019, Volume 380, Issue 1, pp. 45 - 56
Journal Article
Clinical Lymphoma, Myeloma & Leukemia, ISSN 2152-2650, 2014, Volume 14, Issue 5, pp. 335 - 342
Abstract The phosphatidylinositol-3-kinase (PI3K) pathway is well known to regulate a wide variety of essential cellular functions, including glucose... 
Hematology, Oncology and Palliative Medicine | Therapy | Targeted | PI3K | mTor | Akt | Review | Signalling | Lymphoma | CATALYTIC SUBUNIT | PTEN LOSS | ACTIVATION | SOLID TUMORS | PHOSPHOINOSITIDE 3-KINASE | CANCER | B-CELL | ONCOLOGY | PI3K PATHWAY | EMBRYONIC LETHALITY | HEMATOLOGY | PHASE-I | Humans | Neoplasm Proteins - physiology | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Patient Selection | Opportunistic Infections - etiology | TOR Serine-Threonine Kinases - antagonists & inhibitors | Signal Transduction - immunology | Lymphoma - drug therapy | Multicenter Studies as Topic | Protein Processing, Post-Translational - drug effects | Antineoplastic Agents - adverse effects | Lymphoma - enzymology | TOR Serine-Threonine Kinases - physiology | Antineoplastic Agents - pharmacology | Opportunistic Infections - immunology | Gene Expression Regulation, Neoplastic - drug effects | Phosphorylation - drug effects | Isoenzymes - physiology | Disease Susceptibility | Treatment Outcome | Clinical Trials as Topic | Proto-Oncogene Proteins c-akt - physiology | Cell Division - drug effects | Signal Transduction - drug effects | Cell Differentiation - drug effects | Protein Kinase Inhibitors - therapeutic use | Phosphatidylinositol 3-Kinases - physiology | Signal Transduction - physiology | Isoenzymes - antagonists & inhibitors | Proto-Oncogene Proteins c-akt - antagonists & inhibitors
Journal Article
by Maier-Hein, Klaus H and Neher, Peter F and Houde, Jean-Christophe and Côté, Marc-Alexane and Garyfallidis, Eleftherios and Zhong, Jidan and Chamberland, Maxime and Yeh, Fang-Cheng and Lin, Ying-Chia and Ji, Qing and Reddick, Wilburn E and Glass, John O and Chen, David Qixiang and Feng, Yuanjing and Gao, Chengfeng and Wu, Ye and Ma, Jieyan and Renjie, H and Li, Qiang and Westin, Carl Freik and Deslauriers-Gauthier, Samuel and González, J Omar Ocegueda and Paquette, Michael and St-Jean, Samuel and Girard, Gabriel and Rheault, François and Sidhu, Jasmeen and Tax, Chantal M.W and Guo, Fenghua and Mesri, Hamed Y and Dávid, Szabolcs and Froeling, Martijn and Heemskerk, Anneriet M and Leemans, Alexander and Boré, Arnaud and Pinsard, Basile and Bedetti, Christophe and Desrosiers, Matthieu and Brambati, Simona and Doyon, Julien and Sarica, Alessia and Vasta, Roberta and Cerasa, Antonio and Quattrone, Aldo and Yeatman, Jason and Khan, Ali R and Hodges, Wes and Alexander, Simon and Romascano, David and Barakovic, Muhamed and Auría, Anna and Esteban, Oscar and Lemkaddem, Alia and Thiran, Jean-Philippe and Cetingul, H Ertan and Oy, Benjamin L and Mailhe, Boris and Nadar, Mariappan S and Pizzagalli, Fabrizio and Prasad, Gautam and Villalon-Reina, Julio E and Galvis, Justin and Thompson, Paul M and Requejo, Francisco De Santiago and Laguna, Peo Luque and Lacerda, Luis Miguel and Barrett, Rachel and Dell'Acqua, Flavio and Catani, Marco and Petit, Laurent and Caruyer, Emmanuel and Daducci, Alessano and Dyrby, Tim B and Holland-Letz, Tim and Hilgetag, Claus C and Stieltjes, Bram and Descoteaux, Maxime
Nature Communications [E], ISSN 2041-1723, 11/2017, Volume 8, Issue 1, pp. 1349 - 13
Journal Article